Logo image of ERAS

ERASCA INC (ERAS) Stock Fundamental Analysis

NASDAQ:ERAS - Nasdaq - US29479A1088 - Common Stock - Currency: USD

1.41  -0.05 (-3.42%)

After market: 1.41 0 (0%)

Fundamental Rating

3

Overall ERAS gets a fundamental rating of 3 out of 10. We evaluated ERAS against 571 industry peers in the Biotechnology industry. ERAS has a great financial health rating, but its profitability evaluates not so good. ERAS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ERAS has reported negative net income.
ERAS had a negative operating cash flow in the past year.
ERAS had negative earnings in each of the past 5 years.
In the past 5 years ERAS always reported negative operating cash flow.
ERAS Yearly Net Income VS EBIT VS OCF VS FCFERAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

ERAS has a better Return On Assets (-30.09%) than 68.21% of its industry peers.
With a decent Return On Equity value of -35.36%, ERAS is doing good in the industry, outperforming 75.31% of the companies in the same industry.
Industry RankSector Rank
ROA -30.09%
ROE -35.36%
ROIC N/A
ROA(3y)-34.42%
ROA(5y)-41.28%
ROE(3y)-41.77%
ROE(5y)-48.83%
ROIC(3y)N/A
ROIC(5y)N/A
ERAS Yearly ROA, ROE, ROICERAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ERAS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERAS Yearly Profit, Operating, Gross MarginsERAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

ERAS has more shares outstanding than it did 1 year ago.
ERAS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ERAS Yearly Shares OutstandingERAS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M
ERAS Yearly Total Debt VS Total AssetsERAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of 0.94, we must say that ERAS is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.94, ERAS is doing good in the industry, outperforming 65.90% of the companies in the same industry.
There is no outstanding debt for ERAS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.94
ROIC/WACCN/A
WACCN/A
ERAS Yearly LT Debt VS Equity VS FCFERAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M -100M 200M 300M 400M

2.3 Liquidity

ERAS has a Current Ratio of 11.00. This indicates that ERAS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ERAS (11.00) is better than 82.59% of its industry peers.
A Quick Ratio of 11.00 indicates that ERAS has no problem at all paying its short term obligations.
ERAS has a Quick ratio of 11.00. This is amongst the best in the industry. ERAS outperforms 82.59% of its industry peers.
Industry RankSector Rank
Current Ratio 11
Quick Ratio 11
ERAS Yearly Current Assets VS Current LiabilitesERAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.89% over the past year.
EPS 1Y (TTM)50.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ERAS will show a small growth in Earnings Per Share. The EPS will grow by 3.95% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.47%
EPS Next 2Y13.46%
EPS Next 3Y7.2%
EPS Next 5Y3.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ERAS Yearly Revenue VS EstimatesERAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ERAS Yearly EPS VS EstimatesERAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ERAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ERAS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERAS Price Earnings VS Forward Price EarningsERAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERAS Per share dataERAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.46%
EPS Next 3Y7.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ERAS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ERASCA INC

NASDAQ:ERAS (2/21/2025, 8:16:00 PM)

After market: 1.41 0 (0%)

1.41

-0.05 (-3.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-20 2025-03-20/amc
Inst Owners79.8%
Inst Owner Change-0.52%
Ins Owners7.36%
Ins Owner Change0%
Market Cap398.65M
Analysts85.71
Price Target5.1 (261.7%)
Short Float %14.79%
Short Ratio24.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.09%
Min EPS beat(2)-55.48%
Max EPS beat(2)35.3%
EPS beat(4)2
Avg EPS beat(4)-4.67%
Min EPS beat(4)-55.48%
Max EPS beat(4)35.3%
EPS beat(8)5
Avg EPS beat(8)-23.56%
EPS beat(12)8
Avg EPS beat(12)-12.35%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.38%
EPS NQ rev (1m)2.75%
EPS NQ rev (3m)25.81%
EPS NY rev (1m)0%
EPS NY rev (3m)13.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 0.89
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0
BVpS1.59
TBVpS1.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.09%
ROE -35.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.42%
ROA(5y)-41.28%
ROE(3y)-41.77%
ROE(5y)-48.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.7%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11
Quick Ratio 11
Altman-Z 0.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)649.77%
Cap/Depr(5y)463.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
EPS Next Y9.47%
EPS Next 2Y13.46%
EPS Next 3Y7.2%
EPS Next 5Y3.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.93%
EBIT Next 3Y-6.69%
EBIT Next 5YN/A
FCF growth 1Y7.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.34%
OCF growth 3YN/A
OCF growth 5YN/A